FAQ/Help |
Calendar |
Search |
Today's Posts |
12-14-2007, 02:21 PM | #1 | |||
|
||||
Senior Member
|
J Neurochem. 2007 Oct 31 [Epub ahead of print] Links
Therapeutic effects of Coenzyme Q(10) (CoQ(10)) and reduced CoQ(10) in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinsonism.Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, Sireci A, Wille EJ, Beal MF. Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY, USA. Coenzyme Q(10) (CoQ(10)) is a promising agent for neuroprotection in neurodegenerative diseases. We tested the effects of various doses of two formulations of CoQ(10) in food, and found that administration in the diet resulted in significant protection against loss of dopamine, which was accompanied by a marked increase in plasma concentrations of CoQ(10). We further investigated the neuroprotective effects of CoQ(10), reduced CoQ(10) (ubiquinol), and CoQ(10) emulsions in the (MPTP) model of Parkinson's disease (PD). We found neuroprotection against MPTP induced loss of dopamine using both CoQ(10), and reduced CoQ(10), which produced the largest increases in plasma concentrations. Lastly, we administered CoQ(10) in the diet to test its effects in a chronic MPTP model induced by administration of MPTP by Alzet pump for one month. We found neuroprotective effects against dopamine depletion, loss of tyrosine hydroxylase neurons and induction of alpha-synuclein inclusions in the substantia nigra pars compacta. The finding that CoQ(10) is effective in a chronic dosing model of MPTP toxicity, is of particular interest, since this may be more relevant to PD. These results provide further evidence that administration of CoQ(10) is a promising therapeutic strategy for the treatment of PD. PMID: 17973981 [PubMed - as supplied by publisher]
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
Reply With Quote |
12-14-2007, 10:04 PM | #2 | |||
|
||||
Senior Member
|
...Mol Biotechnol. 2007 Sep;37(1):31-7. Links
Bioenergetic and antioxidant properties of coenzyme Q10: recent developments.Littarru GP, Tiano L. Institute of Biochemistry, Polytechnic University of the Marche, Via Ranieri, Ancona 60131, Italy. g.litta...@univpm.it For a number of years, coenzyme Q (CoQ10 in humans) was known for its key role in mitochondrial bioenergetics; later studies demonstrated its presence in other subcellular fractions and in plasma, and extensively investigated its antioxidant role. These two functions constitute the basis on which research supporting the clinical use of CoQ10 is founded. Also at the inner mitochondrial membrane level, coenzyme Q is recognized as an obligatory co-factor for the function of uncoupling proteins and a modulator of the transition pore. Furthermore, recent data reveal that CoQ10 affects expression of genes involved in human cell signalling, metabolism, and transport and some of the effects of exogenously administered CoQ10 may be due to this property. Coenzyme Q is the only lipid soluble antioxidant synthesized endogenously. In its reduced form, CoQH2, ubiquinol, inhibits protein and DNA oxidation but it is the effect on lipid peroxidation that has been most deeply studied. Ubiquinol inhibits the peroxidation of cell membrane lipids and also that of lipoprotein lipids present in the circulation. Dietary supplementation with CoQ10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoproteins to the initiation of lipid peroxidation. Moreover, CoQ10 has a direct anti-atherogenic effect, which has been demonstrated in apolipoprotein E-deficient mice fed with a high-fat diet. In this model, supplementation with CoQ10 at pharmacological doses was capable of decreasing the absolute concentration of lipid hydroperoxides in atherosclerotic lesions and of minimizing the size of atherosclerotic lesions in the whole aorta. Whether these protective effects are only due to the antioxidant properties of coenzyme Q remains to be established; recent data point out that CoQ10 could have a direct effect on endothelial function. In patients with stable moderate CHF (congestive heart failure), oral CoQ10 supplementation was shown to ameliorate cardiac contractility and endothelial dysfunction. Recent data from our laboratory showed a strong correlation between endothelium bound extra cellular SOD (ecSOD)(Super Oxide Dismutase is a powerful enzyme and cellular anti-oxidant that acts as a super-scavenger of dangerous free-radicals) and flow-dependent endothelial-mediated dilation (FMD), a functional parameter commonly used as a biomarker of vascular function. The study also highlighted that supplementation with CoQ10 that significantly affects endothelium- bound ecSOD activity. Furthermore, we showed a significant correlation between increase in endothelial bound ecSOD activity and improvement in FMD after CoQ10 supplementation. The effect was more pronounced in patients with low basal values of ecSOD. Finally, we summarize the findings, also from our laboratory, on the implications of CoQ10 in seminal fluid integrity and sperm cell motility. PMID: 17914161 [PubMed - indexed for MEDLINE]
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Coenzyme Q10? | Parkinson's Disease | |||
Coenzyme Q10, 300 mg good enough? | Parkinson's Disease | |||
Coenzyme Q10 Does Not Improve Parkinson's Disease Symptoms | Parkinson's Disease | |||
Food Study: CoQ10 Coenzyme Q10 or ubiquinone | Gluten Sensitivity / Celiac Disease |